Welcome to our dedicated page for Fibrobiologics SEC filings (Ticker: FBLG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for FibroBiologics, Inc. (Nasdaq: FBLG), a clinical-stage biotechnology company based in Houston that develops fibroblast-based therapies and fibroblast-derived materials for chronic diseases. These regulatory documents offer detailed information on the company’s capital structure, governance, financing arrangements, and stockholder proposals.
FibroBiologics’ filings include Forms 8-K describing material events such as securities purchase agreements, registered direct offerings, concurrent private placement warrants, use of sovereign-issued gold coins as consideration in one offering, and the payoff of convertible promissory notes issued under a Standby Equity Purchase Agreement. Other 8-K filings disclose Nasdaq notices related to minimum bid price and Market Value of Listed Securities requirements, along with the company’s potential options to address these listing standards.
The company’s proxy statements on Schedule 14A outline items submitted to stockholders, including a proposed reverse stock split within a specified ratio range, approvals for issuances of common stock underlying various warrant agreements under Nasdaq Listing Rule 5635(d), and an adjournment proposal. These documents also discuss voting rights, such as the Series C Preferred Stock with super voting rights and the irrevocable proxy in favor of the board of directors.
Through this page, users can review FibroBiologics’ annual and quarterly reports when available, current reports on Form 8-K, and proxy materials, with AI-powered tools that summarize key terms, highlight financing structures, and clarify complex provisions. Investors can also use the filings to understand warrant terms, reverse split authorizations, Nasdaq compliance disclosures, and other regulatory details that shape the risk and capital profile of FBLG.
FibroBiologics, Inc. is registering up to 1,136,363 shares of common stock, up to 1,136,363 pre-funded warrants and related warrants in a best efforts public offering. Each share or pre-funded warrant is sold with a warrant, at an assumed combined price of $4.40. The company estimates net proceeds of about $4.3 million, intended for working capital and general corporate purposes. A 1-for-20 reverse stock split effective March 30, 2026 will reduce outstanding common shares from 70,256,883 to approximately 3,512,845, mainly to help regain Nasdaq bid-price compliance. The offering has no minimum size, may close with reduced proceeds and will cause immediate dilution for new investors.
FibroBiologics, Inc. filed Amendment No. 1 to its 2025 annual report to add the previously omitted Part III sections on directors, executive officers, compensation, security ownership, related‑party transactions and auditor fees. The company states the amendment does not change any prior financial results or other disclosures in the original 2025 report.
FibroBiologics, Inc. updated the compensation of its Chief Financial Officer. On March 4, 2026, the board’s Compensation Committee approved a new annual base salary of $400,000 for CFO Jason D. Davis, effective January 1, 2026. His target for annual non‑equity incentive compensation remains at 40% of base salary.
FibroBiologics, Inc. Chief Scientific Officer Hamid Khoja reported an open-market purchase of 30,000 shares of common stock at $0.3800 per share. Following this transaction, he directly owns 61,250 common shares.
FibroBiologics, Inc. chief executive officer Pete O'Heeron reported open-market purchases of 51,500 shares of common stock across three days. He bought 17,428 shares on March 2, 18,200 on March 3, and 15,872 on March 4, 2026, bringing his direct holdings to 5,958,147 shares.
FibroBiologics, Inc. Chief Financial Officer Jason Davis purchased 70,000 shares of the company’s common stock in an open-market transaction on March 2, 2026. The weighted average purchase price was $0.4139 per share, with individual trade prices ranging from $0.3968 to $0.4200. Following this transaction, Davis directly owns 70,000 common shares.
FibroBiologics, Inc. General Counsel Ruben A. Garcia bought 40,000 shares of common stock in an open-market purchase on February 27, 2026 at a weighted average price of $0.3264 per share. After this transaction, he directly owns 180,000 shares. The filing notes individual trade prices ranged from $0.3221 to $0.3268.
FibroBiologics, Inc. is a clinical-stage biotech company developing fibroblast-based cell therapies for chronic diseases such as wound healing, multiple sclerosis, degenerative disc disease, psoriasis, and longevity-related indications. Its approach uses allogeneic fibroblast single cells and spheroids as a scalable alternative to mesenchymal stem cells.
Lead program CYWC628 targets diabetic foot ulcers, with IND-enabling studies completed and a twelve-week Phase 1/2 trial in Australia planned for the first quarter of 2026. CYMS101 for multiple sclerosis has completed a five-patient Phase 1 safety study in Mexico, with a U.S. Phase 1/2 IND planned for the first half of 2026.
CybroCell™ for degenerative disc disease has supporting animal data and prior FDA IND clearance, while CYPS317 for psoriasis has an FDA Phase 1/2 IND filed on December 30, 2025. Early research programs include CYTER915 for thymus and spleen regeneration, a cancer initiative (TCB190), and an artificial pancreatic organoid program.
FibroBiologics, Inc. held a Special Meeting of Stockholders where all proposals were approved, including a key change to its capital structure. Stockholders authorized the Board to implement a reverse stock split of common and preferred stock at a ratio between 1-for-5 and 1-for-30 at the Board’s discretion within one year of approval. They also approved several proposals under Nasdaq Listing Rule 5635(d) allowing issuance of shares upon exercise of outstanding common warrants tied to prior securities purchase agreements and an engagement letter with H.C. Wainwright & Co., LLC. Attendance represented 54,974,113 votes out of 99,019,722 entitled to vote as of the record date.
FibroBiologics, Inc. reports that Nasdaq has added a second deficiency notice as an additional basis for potential delisting. The company previously failed to meet the minimum bid price requirement and now also remains below Nasdaq’s $35 million minimum market value of listed securities threshold.
A Nasdaq Hearings Panel will review FibroBiologics’ plan to regain compliance with both rules, and the stock will continue trading on The Nasdaq Capital Market at least until the Panel issues its decision and any granted extension expires. To support regaining compliance, the company has filed proxy materials seeking shareholder approval for a reverse stock split at a ratio between 1-for-5 and 1-for-30, to be set by the board. Management cautions there is no assurance the company will receive an extension or successfully regain compliance.